Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) News

Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): $87.93

-1.95 (-2.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter HZNP News Items

HZNP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HZNP News Highlights

  • For HZNP, its 30 day story count is now at 31.
  • Over the past 28 days, the trend for HZNP's stories per day has been choppy and unclear. It has oscillated between 1 and 12.
  • ADVM, AKYA and AXNX are the most mentioned tickers in articles about HZNP.

Latest HZNP News From Around the Web

Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Horizon updates full-year guidance to reflect Viela Bio acquisition

Horizon Therapeutics (HZNP) has revised its full-year net sales and adjusted EBITDA guidance upwards to reflect its acquisition of Viela Bio that closed in March.Net sales are now expected to be between $2.75B to $2.85B, and adjusted EBITDA between $1.02B and $1.06B.For the quarter, Horizon beat on EPS but missed...

Seeking Alpha | May 5, 2021

Was The Smart Money Right About Horizon Therapeutics (HZNP)?

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

Yahoo | May 4, 2021

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Bi...

Benzinga | April 29, 2021

Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide

Horizon Therapeutics plc ranked #4 in overall corporate reputation among pharmaceutical and biotech companies.

Yahoo | April 27, 2021

Top Healthcare Stocks for May 2021

These are the healthcare stocks with the best value, fastest growth, and most momentum for May 2021.

Yahoo | April 22, 2021

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

CHARLOTTESVILLE, Va. , April 21, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc (NASDAQ: HZNP ) that was established in January 2019 . Leveraging its proprietary REVEAL-Tx ™ disease modeling platform, HemoShear has earned two milestone payments to date in accordance with the Horizon exclusive drug discovery agreement. Each milestone acknowledges the validation of a novel drug target and its advancement to a subsequent stage in Horizon's early discovery pipeline. "In two years, Hemoshear has generated and validated … Full story available on Benzinga.com

Benzinga | April 21, 2021

3 Reasons to Buy Horizon Therapeutics Stock and 1 Not To

Horizon Therapeutics's shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug.

Yahoo | April 17, 2021

New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics today announced new UPLIZNA® (inebilizumab-cdon) data being presented at the American Academy of Neurology 2021 Annual Meeting.

Yahoo | April 16, 2021

New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology

Horizon Therapeutics announced pooled data from the TEPEZZA® (teprotumumab-trbw) clinical trials are published in The Lancet Diabetes & Endocrinology.

Yahoo | April 16, 2021

Biotech Stock On Earnings Win Streak Sets Up Bullish Chart

Biotech stock Horizon Therapeutics is set up below a buy point, ahead of earnings, after soaring 102% in 2020. Can it do it again?

Yahoo | April 12, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6283 seconds.